Authors' replyBMJ 1996; 312 doi: https://doi.org/10.1136/bmj.312.7025.254a (Published 27 January 1996) Cite this as: BMJ 1996;312:254
- Giancarlo Viberti,
- R John Jarrett
- For the Microalbuminuria Collaborative Study Group Professor of diabetes and metabolic medicine Retired professor of clinical epidemiology Department of Metabolic Medicine and Endocrinology, Division of Medicine, UMDS, Guy's Hospital, London SE1 9RT
EDITOR,—Nish Chaturvedi and John H Fuller point to a limitation of our study—the sample size—which we acknowledged in our paper. A larger sample size was planned, but screening yielded fewer suitable patients than expected. Nevertheless, this is the largest study of the kind published to date, and its size in combination with that of the subgroup with microalbuminuria in the diabetes control and complications trial1 could detect a reduction in the risk of progression to clinical albuminuria of 33% or more. Neither study showed any effect of intensive treatment on the categorical change from microalbuminuria to clinical albuminuria.
In the 73 patients with insulin dependent diabetes mellitus and baseline microalbuminuria in the diabetes control and complications …